Supplementary Material

Manuscript Title: "A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives."

Authors: Daniel Nascimento do Amaral, Jonas Lategahn, Harold Hilarion Fokoue, Eduardo Miguez Bastos da Silva, Carlos Mauricio R. Sant'Anna, Daniel Rauh, Eliezer J. Barreiro, Stefan Laufer*,Lídia Moreira Lima *



Figure S1: Simple docking best poses for compounds **7j** and **7k,** with electrophilic carbon of the α-carbon of carbonyl subunit, in the ATP binding site of EGFRwt. (A) Superposition of **7j** and **7k**; (B) Interaction profile of compound **7j** (*carbon atoms in yellow*); (C) Interaction profile of compound **7i** (*carbon atoms in orange*). *Dashed gray lines*: Hydrogen bonds.



Figure S2: Simple docking best poses for compounds **7h, 7i and 7l**, with electrophilic carbon of the enone subunit, in the ATP binding site of $EGFR_{wt}$. (A) Superposition of **7h, 7i and 7l**; (B) Interaction profile of compound **7h** (*carbon atoms in green*); (C) Interaction profile of compound **7i** (*carbon atoms in blue*); (D) Interaction profile of compound **7l** (*carbon atoms in magenta*). *Dashed gray lines*: Hydrogen bonds.



Figure S3: Covalent docking best poses for compounds **7j** and **7k,** with electrophilic carbon of the α-carbon of carbonyl subunit, in the ATP binding site of $EGFR_{wt}$. (A) Superposition of **7j** and **7k**; (B) Interaction profile of compound **7j** (*carbon atoms in yellow*); (C) Interaction profile of compound **7k** (*carbon atoms in orange*). *Dashed gray lines*: Hydrogen bonds.



Figure S4: Covalent docking best poses for compounds **7h, 7i and 7l**, with electrophilic carbon of the enone subunit, in the ATP binding site of $EGFR_{wt}$. (A) Superposition of **7h, 7i and 7l**; (B) Interaction profile of compound **7h** (*carbon atoms in green*); (C) Interaction profile of compound **7i** (*carbon atoms in blue*); (D) Interaction profile of compound **7l** (*carbon atoms in magenta*). *Dashed gray lines*: Hydrogen bonds.



Figure S5. ^{1}H NMR spectrum of compound 1-(7-nitroquinoxalin-2-yl)-3-(4-chloro-3 (trifluormethyl)phenyl)urea **(9a)** (DMSO-d_6/200MHz/TMS).



Figure S6. ^{1}H NMR spectrum of compound 1-(7-nitroquinoxalin-2-yl)-3-(4-chloro-3-(trifluormethyl)phenyl)urea **(9a)** (pyridine-d_5/200MHz/TMS)



Figure S7. ^{13}C NMR spectrum of compound 1-(7-nitroquinoxalin-2-yl)-3-(4-chloro-3-(trifluormethyl)phenyl)urea **(9a)** (pyridine-d_5/200MHz/TMS)



Figure S8. Mass spectrometry of compound 1-(7-nitroquinoxalin-2-yl)-3-(4-chloro-3-(trifluormethyl) phenyl)urea **(9a)** in negative mode (ESI-).



Figure S9. Infra red spectrum (ATR-FTIR) of compound 1-(7-nitroquinoxalin-2-yl)-3-(4-chloro-3-(trifluormethyl)phenyl)urea **(9a)** (bands in cm^{-}).



Figure S10. ^{1}H NMR spectrum of compound 1-(7-nitroquinoxalin-2-yl)-3-(3-(trifluormethyl) phenyl)urea **(9b)** (DMSO-d_6/200MHz/TMS)



Figure S11. ^{13}C NMR spectrum of compound 1-(7-nitroquinoxalin-2-yl)-3-(3-(trifluormethyl)phenyl) **(9b)** (DMSO-d_6/50MHz/TMS)



Figure S12. Mass spectrometry of compound 1-(7-nitroquinoxalin-2-yl)-3-(3-(trifluormethyl)phenyl) urea **(9b)** in negative mode (ESI-).



Figure S13. Infra red spectrum (ATR-FTIR) of compound 1-(7-nitroquinoxalin-2-yl)-3-(3-(trifluormethyl) phenyl) urea **(9b)** (bands in cm^{-}).



Figure S14. ^{1}H NMR spectrum of compound 1-(7-nitroquinoxalin-2-yl)-3-phenylurea **(9c)** (DMSO-d_6/200MHz/TMS)



Figure S15. ^{13}C NMR spectrum of compound 1-(7-nitroquinoxalin-2-yl)-3-phenylurea **(9c)** (DMSO-d_6/50MHz/TMS)



Figure S16. Mass spectrometry of compound 1-(7-nitroquinoxalin-2-yl)-3-phenylurea **(9c)** in negative mode (ESI-).



Figure S17. Infra red spectrum (ATR-FTIR) of compound 1-(7-nitroquinoxalin-2-yl)-3-phenylurea **(9c)** (bands in cm^{-}).



Figure S18. ^{1}H NMR spectrum of compound 1-(3-chloro-4-fluorophenyl)-3-(7-nitroquinoxalin-2-yl)urea **(9d)** (DMSO-d_6/200MHz/TMS)



Figure S19. ^{13}C NMR spectrum of compound 1-(3-chloro-4-fluorophenyl)-3-(7-nitroquinoxalin-2-yl)urea **(9d)** (DMSO-d_6/50MHz/TMS)



Figure S20. Mass spectrometry of compound 1-(3-chloro-4-fluorophenyl)-3-(7-nitroquinoxalin-2-yl)urea **(9d)** in negative mode (ESI-).



Figure S21. Infra red spectrum (ATR-FTIR) of compound 1-(3-chloro-4-fluorophenyl)-3-(7-nitroquinoxalin-2-yl)urea **(9d)** (bands in cm^{-}).



Figure S22. ^{1}H NMR spectrum do 1-(7-aminoquinoxalin-2-yl)-3-(4-chloro-3-(trifluoromethyl)phenyl)urea **(10a)** (DMSO-d_6/200MHz/TMS)



Figure S23. ^{13}C NMR spectrum of compound 1-(7-aminoquinoxalin-2-yl)-3-(4-chloro-3-(trifluoromethyl) phenyl)urea **(10a)** (DMSO-d_6/100MHz/TMS)



Figure S24. Espectro de DEPT 135 of compound 1-(7-aminoquinoxalin-2-yl)-3-(4-chloro-3-(trifluoromethyl) phenyl)urea **(10a)** (DMSO-d_6/100MHz/TMS)



Figure S25. Mass spectrometry of compound 1-(7-aminoquinoxalin-2-yl)-3-(4-chloro-3-(trifluormethyl) phenyl) urea **(10a)** in negative mode (ESI-).



Figure S26. Infra red spectrum (ATR-FTIR) of compound 1-(7-aminoquinoxalin-2-yl)-3-(4-chloro-3-(trifluormethyl) phenyl) urea **(10a)** (bands in cm^{-}).



Figure S27. ^{1}H NMR spectrum of compound 1-(7-aminoquinoxalin-2-yl)-3-(3-(trifluormethyl)phenyl) urea **(10b)** (DMSO-d_6/200MHz/TMS)



Figure S28. ^{13}C NMR spectrum of compound 1-(7-aminoquinoxalin-2-yl)-3-(3-(trifluormethyl)phenyl) urea **(10b)** (DMSO-d_6/50MHz/TMS)



Figure S29. Mass spectrometry of compound 1-(7-aminoquinoxalin-2-yl)-3-(3-(trifluormethyl)phenyl) urea **(10b)** in negative mode (ESI-).



Figure S30. Infra red spectrum (ATR-FTIR) of compound 1-(7-aminoquinoxalin-2-yl)-3-(3-(trifluormethyl)phenyl) urea **(10b)** (bands in cm^{-}).



Figure S31. ^{1}H NMR spectrum of compound 1-(7-aminoquinoxalin-2-yl)-3-phenylurea **(10c)** (DMSO-d_6/200MHz/TMS)



Figure S32. ^{13}C NMR spectrum of compound 1-(7-aminoquinoxalin-2-yl)-3-phenylurea **(10c)** (DMSO-d_6/50MHz/TMS)



Figure S33. Mass spectrometry of compound 1-(7-aminoquinoxalin-2-yl)-3-phenylurea **(10c)** in negative mode (ESI-).



Figure S34. Infra red spectrum (ATR-FTIR) of compound 1-(7-aminoquinoxalin-2-yl)-3-phenylurea **(10c)** (bands in cm^{-})



Figure S35. ^{1}H NMR spectrum of compound 1 - (7-aminoquinoxalin-2-yl)-3-(3-chloro-4-fluorophenyl) urea **(10d)** (DMSO-d_6/200MHz/TMS)



Figure S36. Mass spectrometry of compound 1 - (7-aminoquinoxalin-2-yl)-3-(3-chloro-4-fluorophenyl) urea **(10d)** in negative mode (ESI-).



Figure S37. Infra red spectrum (ATR-FTIR) of compound 1 - (7-aminoquinoxalin-2-yl)-3-(3-chloro-4-fluorophenyl) urea **(10d)** (bands in cm^{-}).



Figure S38. ^{1}H NMR spectrum of compound *N*-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido)quinoxalin-6-yl)acrylamide **(7a)** (DMSO-d_6/200MHz/TMS)



Figure S39. ^{13}C NMR spectrum of compound *N*-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido)quinoxalin-6-yl)acrylamide **(7a)** (DMSO-d_6/50MHz/TMS)



Figure S40. Mass spectrometry of compound *N*-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido) quinoxalin-6-yl) acrylamide **(7a)** in negative mode (ESI-).



Figure S41. Infra red spectrum (ATR-FTIR) of compound *N*-(3-(3-(4-chloro-3-(trifluoromethyl) phenyl)ureido) quinoxalin-6-yl) acrylamide **(7a)** (bands in cm^{-}).



Figure S42. ^{1}H NMR spectrum of compound (*E*)-*N*-(3-(3-(4-chloro-3-(trifluoromethyl) phenyl)ureido)quinoxalin-6-yl)but-2-enamide **(7b)** (DMSO-d_6/200MHz/TMS)



Figure S43. ^{13}C NMR spectrum of compound (*E*)-*N*-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)quinoxalin-6-yl)but-2-enamide **(7b)** (DMSO-d_6/50MHz/TMS).



Figure S44. Mass spectrometry of compound (*E*)-*N*-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido) quinoxalin-6-yl)but-2-enamide **(7b)** in negative mode (ESI-).



Figure S45. Infra red spectrum (ATR-FTIR) of compound (*E*)-*N*-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido) quinoxalin-6-yl)but-2-enamide **(7b)** (bands in cm^{-}).



Figure S46. ^{1}H NMR spectrum of compound 2-chloro-*N*-(3-(3-(4-chloro-3-(trifluoromethyl) phenyl)ureido) quinoxalin-6-yl)acetamide **(7c)** (DMSO-d_6/200MHz/TMS)



Figure S47. ^{13}C NMR spectrum of compound 2-chloro-*N*-(3-(3-(4-chloro-3-(trifluoromethyl) phenyl)ureido) quinoxalin-6-yl)acetamide **(7c)** (DMSO-d_6/50MHz/TMS)



Figure S48. Mass spectrometry of compound 2-chloro-*N*-(3-(3-(4-chloro-3-(trifluoromethyl) phenyl)ureido) quinoxalin-6-yl)acetamide **(7c)** in negative mode (ESI-).



Figure S49. Infra red spectrum (ATR-FTIR) of compound 2-chloro-*N*-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido) quinoxalin-6-yl)acetamide **(7c)** (bands in cm^{-}).



Figure S50. ^{1}H NMR spectrum of compound 2-chloro- *N*-(3-(3-(4-chloro-3-(trifluoromethyl) phenyl)ureido)quinoxalin-6-yl)-2-cianoacetamide **(7d)** (DMSO-d_6/200MHz/TMS)



Figure S51. ^{13}C NMR spectrum of compound 2-chloro- *N*-(3-(3-(4-chloro-3-(trifluoromethyl) phenyl)ureido)quinoxalin-6-yl)-2-cianoacetamide **(7d)** (DMSO-d_6/50MHz/TMS)



Figure S52. Mass spectrometry of compound *N*-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido) quinoxalin-6-yl) -2-cianoacetamide **(7d)** in negative mode (ESI-).



Figure S53. Infra red spectrum (ATR-FTIR) of compound *N*-(3-(3-(4-chloro-3-(trifluoromethyl) phenyl)ureido) quinoxalin-6-yl)-2-cianoacetamide **(7d)** (bands in cm^{-}).



Figure S54. ^{1}H NMR spectrum of compound (*E*)-*N*-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido)quinoxalin-6-yl)-4-(dimethylamino)but-2-enamide **(7e)** (DMSO-d_6/200MHz/TMS)



Figure S55. ^{13}C NMR spectrum of compound (*E*)-*N*-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido)quinoxalin-6-yl)-4-(dimethylamino)but-2-enamide **(7e)** (DMSO-d_6/150MHz/TMS)



Figure S56. HSQC spectrum of compound (*E*)-*N*-(3-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)quinoxalin-6-yl)-4-(dimethylamino)but-2-enamide **(7e)** (DMSO-d_6/150MHz/TMS)



Figure S57. Mass spectrometry of compound *E*)-*N*-(3-(3-(4-chloro-3-(trifluoromethyl) phenyl)ureido) quinoxalin-6-yl)-4-(dimethylamino)but-2-enamide **(7e)** in negative mode (ESI-).



Figure S58. Infra red spectrum (ATR-FTIR) of compound (*E*)-*N*-(3-(3-(4-chloro-3-(trifluoromethyl) phenyl)ureido) quinoxalin-6-yl)-4-(dimethylamino)but-2-enamide **(7e)** (bands in cm^{-}).



Figure S59. ^{1}H NMR spectrum of compound *N*-(3-(3-(3-(trifluoromethyl)phenyl)ureido) quinoxalin-6-yl)acrylamide **(7f)** (DMSO-d_6/200MHz/TMS)



Figure S60. ^{13}C NMR spectrum of compound *N*-(3-(3-(3-(trifluoromethyl)phenyl)ureido) quinoxalin-6-yl)acrylamide **(7f)** (DMSO-d_6/50MHz/TMS)



Figure S61. Mass spectrometry of compound *N*-(3-(3-(3-(trifluoromethyl)phenyl)ureido) quinoxalin-6-yl) acrylamide **(7f)** in negative mode (ESI-)



Figure S62. Infra red spectrum (ATR-FTIR) do *N*-(3-(3-(3-(trifluoromethyl)phenyl)ureido) quinoxalin-6-yl)acrylamide **(7f)** (bands in cm^{-}).



Figure S63. ^{1}H NMR spectrum of compound 2-chloro-*N*-(3-(3-(3-(trifluoromethyl) phenyl)ureido) quinoxalin-6-yl) acetamide**(7g)** (DMSO-d_6/200MHz/TMS)



Figure S64. ^{13}C NMR spectrum of compound 2-chloro-*N*-(3-(3-(3-(trifluoromethyl)phenyl) ureido) quinoxalin-6-yl) acetamide **(7g)** (DMSO-d_6/50MHz/TMS)



Figure S65. Mass spectrometry of compound 2-chloro-*N*-(3-(3-(3-(trifluoromethyl)phenyl) ureido) quinoxalin-6-yl) acetamide **(7g)** in negative mode (ESI-).



Figure S66. Infra red spectrum (ATR-FTIR) do 2-chloro-*N*-(3-(3-(3-(trifluoromethyl)phenyl) ureido) quinoxalin-6-yl) acetamide **(7g)** (bands in cm^{-}).



Figure S67. ^{1}H NMR spectrum of compound *N*-(3-(3-phenylureido)quinoxalin-6-yl)acrylamide **(7h)** (DMSO-d_6/200MHz/TMS)



Figure S68. ^{13}C NMR spectrum of compound *N*-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide **(7h)** (DMSO-d_6/50MHz/TMS)



Figure S69. Mass spectrometry of compound *N*-(3-(3-phenylureido)quinoxalin-6-yl)acrylamide **(7h)** in negative mode (ESI-).



Figure S70. Infra red spectrum (ATR-FTIR) of compound *N*-(3-(3-phenylureido)quinoxalin-6-yl)acrylamide **(7h)** (bands in cm^{-}).



Figure S71. ^{1}H NMR spectrum of compound 1(*E*)-*N*-(3-(3-phenylureido)quinoxalin-6-yl)but-2-enamide **(7i)** (DMSO-d_6/200MHz/TMS)



Figure S72. ^{13}C NMR spectrum of compound (*E*)-*N*-(3-(3-phenylureido)quinoxalin-6-yl)but-2-enamide **(7i)** (DMSO-d_6/50MHz/TMS)



Figure S73. Mass spectrometry of compound (*E*)-*N*-(3-(3-phenylureido)quinoxalin-6-yl)but-2-enamide **(7i)** in negative mode (ESI-).



Figure S74. Infra red spectrum (ATR-FTIR) of compound (*E*)-*N*-(3-(3-phenylureido)quinoxalin-6-yl)but-2-enamide **(7i)** (bands in cm^{-}).



Figure S75. ^{1}H NMR spectrum of compound 2-chloro-*N*-(3-(3-phenylureido)quinoxalin-6-yl)acetamide **(7j)** DMSO-d_6/200MHz/TMS)



Figure S76. ^{13}C NMR spectrum do 2-chloro-*N*-(3-(3-phenylureido)quinoxalin-6-yl)acetamide **(7j)** (DMSO-d_6/50MHz/TMS)



Figure S77. Mass spectrometry of compound 2-chloro-*N*-(3-(3-phenylureido)quinoxalin-6-yl) acetamide **(7j)** in negative mode (ESI-).



Figure S78. Infra red spectrum (ATR-FTIR) of compound 2-chloro-*N*-(3-(3-phenylureido) quinoxalin-6-yl)acetamide **(7j)** (bands in cm^{-}).



Figure S79. ^{1}H NMR spectrum of compound 2-ciano-*N*-(3-(3-phenylureido)quinoxalin-6-yl)acetamide **(7k)** (DMSO-d_6/200MHz/TMS)



Figure S80. ^{13}C NMR spectrum of compound 2-ciano-*N*-(3-(3-phenylureido)quinoxalin-6-yl)acetamide **(7k)** (DMSO-d_6/50MHz/TMS)



Figure S81. Mass spectrometry of compound 2-ciano-*N*-(3-(3-phenylureido)quinoxalin-6-yl) acetamide **(7k)** in negative mode (ESI-).



Figure S82. [1]H NMR spectrum of compound (*E*)-4-(dimethylamino)-*N*-(3-(3-phenylureido) quinoxalin-6-yl)but-2-enamide **(7l)** (DMSO-d_6/200MHz/TMS)



Figure S83. [13]C NMR spectrum of compound *E*)-4-(dimethylamino)-*N*-(3-(3-phenylureido) quinoxalin-6-yl)but-2-enamide **(7l)** (DMSO-d_6/50MHz/TMS)



Figure S84. Espectro de DEPT 135 of compound *E*)-4-(dimethylamino)-*N*-(3-(3-phenylureido)quinoxalin-6-yl)but-2-enamide **(7l)** (DMSO-d_6/50MHz/TMS).



Figure S85. Mass spectrometry of compound (*E*)-4-(dimethylamino)-*N*-(3-(3-phenylureido) quinoxalin-6-yl)but-2-enamide **(7l)** in negative mode (ESI-).



Figure S86. Infra red spectrum (ATR-FTIR) of compound (*E*)-4-(dimethylamino)-*N*-(3-(3-phenylureido) quinoxalin-6-yl)but-2-enamide **(7l)** (bands in cm^{-}).



Figure S87. ^{1}H NMR spectrum of compound *N*-(3-(3-(3-chloro-4-fluorophenyl) ureido)quinoxalin-6-yl) acrylamide **(7m)** (DMSO-d_6/200MHz/TMS)



Figure S88. ^{13}C NMR spectrum of compound *N*-(3-(3-(3-chloro-4-fluorophenyl)ureido) quinoxalin-6-yl) acrylamide **(7m)** (DMSO-d_6/50MHz/TMS)



Figure S89. Mass spectrometry of compound *N*-(3-(3-(3-chloro-4-fluorophenyl)ureido) quinoxalin-6-yl) acrylamide **(7m)** in negative mode (ESI-).



Figure S90. Infra red spectrum (ATR-FTIR) of compound *N*-(3-(3-(3-chloro-4-fluorophenyl) ureido)quinoxalin-6-yl) acrylamide **(7m)** (bands in cm^{-}).



Figure S91. NOESY 1D spectrum of of compound 1-(7-nitroquinoxalin-2-yl)-3-phenylurea **(9c)** with irradiation at 7.68 ppm (DMSO-d_6/300MHz/TMS)



Figure S92. NOESY 1D spectrum of of compound 1-(7-nitroquinoxalin-2-yl)-3-phenylurea **(9c)** with irradiation at 9.18 ppm (DMSO-d_6/300MHz/TMS)



Figure S93. NOESY 1D spectrum of compound *N*-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide **(7h)** with irradiation at 8.91 ppm (DMSO-d_6/300MHz/TMS)



Figure S94. NOESY 1D spectrum of compound *N*-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide **(7h)** with irradiation at 7.58 ppm (DMSO-d_6/300MHz/TMS)